SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Goltsev Yury)
 

Sökning: WFRF:(Goltsev Yury) > National Cancer Ins...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006984naa a2200733 4500
001oai:DiVA.org:kth-300767
003SwePub
008210909s2020 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-3007672 URI
0247 a https://doi.org/10.1021/acs.jproteome.0c000212 DOI
040 a (SwePub)kth
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Kagan, Jacobu NCI, Canc Biomarkers Res Grp, Div Canc Prevent, Bethesda, MD 20892 USA.4 aut
2451 0a National Cancer Institute Think-Tank Meeting Report on Proteomic Cartography and Biomarkers at the Single-Cell Level :b Interrogation of Premalignant Lesions
264 c 2020-03-12
264 1b American Chemical Society (ACS),c 2020
338 a print2 rdacarrier
500 a QC 20210909
520 a A Think-Tank Meeting was convened by the National Cancer Institute (NCI) to solicit experts' opinion on the development and application of multiomic single-cell analyses, and especially single-cell proteomics, to improve the development of a new generation of biomarkers for cancer risk, early detection, diagnosis, and prognosis as well as to discuss the discovery of new targets for prevention and therapy. It is anticipated that such markers and targets will be based on cellular, subcellular, molecular, and functional aberrations within the lesion and within individual cells. Single-cell proteomic data will be essential for the establishment of new tools with searchable and scalable features that indude spatial and temporal cartographies of premalignant and malignant lesions. Challenges and potential solutions that were discussed included (i) The best way/s to analyze single-cells from fresh and preserved tissue; (ii) Detection and analysis of secreted molecules and from single cells, especially from a tissue slice; (iii) Detection of new, previously undocumented cell type/s in the premalignant and early stage cancer tissue microenvironment; (iv) Multiomic integration of data to support and inform proteomic measurements; (v) Subcellular organelles-identifying abnormal structure, function, distribution, and location within individual premalignant and malignant cells; (vi) How to improve the dynamic range of single-cell proteomic measurements for discovery of differentially expressed proteins and their post-translational modifications (PTM); (vii) The depth of coverage measured concurrently using single-cell techniques; (viii) Quantitation - absolute or semiquantitative? (ix) Single methodology or multiplexed combinations? (x) Application of analytical methods for identification of biologically significant subsets; (xi) Data visualization of N-dimensional data sets; (xii) How to construct intercellular signaling networks in individual cells within premalignant tumor microenvironments (TME); (xiii) Associations between intrinsic cellular processes and extrinsic stimuli; (xiv) How to predict cellular responses to stress-inducing stimuli; (xv) Identification of new markers for prediction of progression from precursor, benign, and localized lesions to invasive cancer, based on spatial and temporal changes within individual cells; (xvi) Identification of new targets for immunoprevention or immunotherapy-identification of neoantigens and surfactome of individual cells within a lesion.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinsk bioteknologi0 (SwePub)3042 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Medical Biotechnology0 (SwePub)3042 hsv//eng
653 a single-cell proteomics
653 a single-cell mass spectrometry
653 a targeted proteomics
653 a precursor lesion
653 a precancer
653 a tumorigenic lesion
653 a lesion's heterogeneity
653 a clonal evolution
653 a spatial and temporal cartography
653 a biomarkers
653 a early detection
653 a targets for prevention and therapy
7001 a Moritz, Robert L.u Inst Syst Biol, Seattle, WA 98109 USA.4 aut
7001 a Mazurchuk, Richardu NCI, Canc Biomarkers Res Grp, Div Canc Prevent, Bethesda, MD 20892 USA.4 aut
7001 a Lee, Je Hyuku Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.4 aut
7001 a Kharchenko, Peter Vasiliu Harvard Med Sch, Blavatn Inst Biomed Informat, Boston, MA 02115 USA.4 aut
7001 a Rozenblatt-Rosen, Oritu Broad Inst, Klarman Cell Observ, Boston, MA USA.4 aut
7001 a Ruppin, Eytanu NCI, Canc Data Sci Lab, Ctr Canc Res, Bethesda, MD 20892 USA.4 aut
7001 a Edfors, Fredriku KTH,Science for Life Laboratory, SciLifeLab,Systembiologi4 aut0 (Swepub:kth)u149ml0e
7001 a Ginty, Fionau GE Global Res Ctr, Life Sci & Mol Diagnost Lab, Niskayuna, NY USA.4 aut
7001 a Goltsev, Yuryu Stanford Univ, Stanford Med Sch, Dept Microbiol & Immunol, Baxter Lab Stem Cell Biol, Stanford, CA 94305 USA.4 aut
7001 a Wells, James A.u Univ Calif San Francisco, Dept Pharmaceut Sci, San Francisco, CA 94143 USA.4 aut
7001 a LaCava, Johnu Rockefeller Univ, Lab Cellular & Struct Biol, 1230 York Ave, New York, NY 10021 USA.4 aut
7001 a Riesterer, Jessica L.u Oregon Hlth & Sci Univ, Ctr Spatial Syst Biomed, Portland, OR 97201 USA.4 aut
7001 a Germain, Ronald N.u NIAID, Lab Immune Syst Biol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.4 aut
7001 a Shi, Tujinu Pacific Northwest Natl Lab, Biol Sci Div, Richland, WA 99352 USA.4 aut
7001 a Chee, Mark S.u Encodia Inc, San Diego, CA USA.4 aut
7001 a Budnik, Bogdan A.u Harvard Univ, Fac Arts & Sci, Div Sci, Boston, MA 02115 USA.4 aut
7001 a Yates, John R., IIIu Scripps Res Inst, Dept Mol Med, La Jolla, CA USA.4 aut
7001 a Chait, Brian T.u Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, 1230 York Ave, New York, NY 10021 USA.4 aut
7001 a Moffitt, Jeffery R.u Boston Childrens Hosp, Boston, MA USA.;Harvard Univ, Med Sch, Boston, MA 02115 USA.4 aut
7001 a Smith, Richard D.u Pacific Northwest Natl Lab, Biol Sci Div, Richland, WA 99352 USA.4 aut
7001 a Srivastava, Sudhiru NCI, Canc Biomarkers Res Grp, Div Canc Prevent, Bethesda, MD 20892 USA.4 aut
7102 a NCI, Canc Biomarkers Res Grp, Div Canc Prevent, Bethesda, MD 20892 USA.b Inst Syst Biol, Seattle, WA 98109 USA.4 org
7730 t Journal of Proteome Researchd : American Chemical Society (ACS)g 19:5, s. 1900-1912q 19:5<1900-1912x 1535-3893x 1535-3907
8564 u https://www.osti.gov/biblio/1639039
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-300767
8564 8u https://doi.org/10.1021/acs.jproteome.0c00021

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy